Manfredi Riccardo, Graziani Rossella, Cicero Calogero, Frulloni Luca, Carbognin Giovanni, Mantovani William, Mucelli Roberto Pozzi
Department of Radiology, University of Verona, Verona, Italy.
Radiology. 2008 May;247(2):435-43. doi: 10.1148/radiol.2472070598.
To retrospectively evaluate the computed tomographic (CT) patterns of autoimmune pancreatitis (AIP) and their changes after steroid therapy.
Investigational review board approval was obtained, and the informed consent requirement was waived. The medical and imaging data of 21 patients (13 men, eight women; mean age, 47.5 years; age range, 25-79 years) with histopathologically proved AIP who underwent contrast material-enhanced CT at diagnosis and after steroid treatment were included in this study. Image analysis included assessment of the (a) presence or absence and type (focal or diffuse) of pancreatic parenchyma enlargement, (b) contrast enhancement of pancreatic parenchyma, (c) size of the main pancreatic duct (MPD) within the lesion and upstream, and (d) pancreatic parenchyma thickness in the head, body, and tail of the pancreas. The same criteria were applied to follow-up CT examinations, the follow-up data were compared with pretreatment data, and a paired sample t test was applied.
Pancreatic parenchyma showed focal enlargement in 14 (67%) patients and diffuse enlargement in seven (33%). Pancreatic parenchyma affected by AIP appeared hypoattenuating in 19 (90%) patients and isoattenuating in two (10%). During the portal venous phase, pancreatic parenchyma showed contrast material retention in 18 (86%) patients and contrast material washout in three (14%). The MPD was never visible within the lesion. After treatment, there was a reduction in the size of pancreatic parenchyma segments affected by AIP (P < .05). Fifteen (71%) of the 21 patients had a normal enhancement pattern in the pancreatic parenchyma, whereas the enhancement pattern remained hypovascular in six (29%). The MPD returned to its normal size within the lesion in all patients at follow-up CT. In one of the eight patients with focal forms of AIP, the upstream MPD remained dilated.
AIP appeared as pancreatic parenchyma enlargement, with MPD stenosis within the lesion and upstream dilatation in focal forms of AIP. After steroid treatment, there was normalization of these findings.
回顾性评估自身免疫性胰腺炎(AIP)的计算机断层扫描(CT)表现及其在类固醇治疗后的变化。
本研究获得了研究审查委员会的批准,并豁免了知情同意的要求。本研究纳入了21例经组织病理学证实为AIP的患者(13例男性,8例女性;平均年龄47.5岁;年龄范围25 - 79岁),这些患者在诊断时及类固醇治疗后均接受了对比剂增强CT检查。图像分析包括评估:(a)胰腺实质增大的有无及类型(局灶性或弥漫性);(b)胰腺实质的对比增强情况;(c)病变内及上游主胰管(MPD)的大小;(d)胰腺头部、体部和尾部的胰腺实质厚度。对随访CT检查采用相同标准,将随访数据与治疗前数据进行比较,并应用配对样本t检验。
14例(67%)患者胰腺实质呈局灶性增大,7例(33%)呈弥漫性增大。19例(90%)受AIP影响的胰腺实质呈低密度,2例(10%)呈等密度。在门静脉期,18例(86%)患者胰腺实质出现对比剂滞留,3例(14%)出现对比剂廓清。病变内从未见MPD显影。治疗后,受AIP影响的胰腺实质节段大小减小(P <.05)。21例患者中有15例(71%)胰腺实质增强模式正常,而6例(29%)增强模式仍为低血供。在随访CT检查中,所有患者病变内的MPD均恢复至正常大小。在8例局灶型AIP患者中的1例,其上游MPD仍扩张。
AIP表现为胰腺实质增大,病变内MPD狭窄,局灶型AIP上游扩张。类固醇治疗后,这些表现恢复正常。